Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Sep 1;17(9):e0273018. doi: 10.1371/journal.pone.0273018

Interventional embolization combined with surgical resection for treatment of extracranial AVM of the head and neck: A monocentric retrospective analysis

Daniel Lilje 1, Martin Wiesmann 1, Dimah Hasan 1,#, Hani Ridwan 1,#, Frank Hölzle 2,#, Omid Nikoubashman 1,*
Editor: Andrej M Kielbassa3
PMCID: PMC9436082  PMID: 36048777

Abstract

Objectives

The aim of this study was to demonstrate the efficacy and feasibility of treating patients with extracranial arteriovenous malformations (AVM) of the head and neck with interventional embolization followed by surgical resection.

Methods

We reviewed the charts of all patients between 2012 and 2021 with extracranial AVM of the head and neck scheduled for interdisciplinary treatment according to University Hospital RWTH Aachen’s protocol and conducted standardized interviews using a newly developed questionnaire. Interview results, as well as clinical examination and radiographic outcome results were analyzed to help determine the efficacy of our treatment approach.

Results

We included 10 patients (8 female, 2 male), with a mean age of 33.5 (11–61) years who were scheduled for treatment of the AVM with interventional embolization followed by surgical resection. In 6 of the 10 patients (60%) the lesion was located in extracranial soft tissue only. In one patient (10%), the lesion was located in bone tissue only. A combined intraosseous and oral soft tissue lesion was seen in the remaining 3 patients (30%). Radiographic resolution was achieved in 62.5% of cases and a significant decrease of symptoms was identified (p = 0.002). None of the patients reported dissatisfaction and no major complications occurred.

Conclusion

An interdisciplinary treatment approach combining neuroradiological interventions with surgical resection appears to be an effective treatment with an acceptable complication rate. Patients treated according to our protocol showed a high satisfaction rate, regardless of the radiographic outcome. Standardized follow-up allows for early detection of recurrences and helps with subjective patient satisfaction.

Introduction

Extracranial arteriovenous malformations (AVM) are rare vascular anomalies. These lesions are known to develop during early gestation and can be evident at birth [1]. They have a tendency to grow over time and become more prominent under the influence of trauma or hormonal changes during puberty or pregnancy [2].

According to the International Society of the Study of Vascular Anomalies (ISSVA), AVM are lesions of a benign nature that directly connect arteries with veins, and are lacking a capillary bed [3], leading to dilated and tortuous draining veins and deformities of the surrounding body region. Clinical presentation varies from slight discoloration and swelling of the skin to ulceration and gross disfigurement. Symptoms may include pain, a throbbing or pulsating sensation, discoloration, ulceration and even life-threatening haemorrhages [4]. In rare occasions, cardiovascular compromise with congestive heart failure has been reported [5]. All AVM symptoms potentially limit the patient’s quality of life.

Established treatments for these lesions include conservative observation, transvascular embolization, percutaneous sclerotherapy and surgical excision. These strategies can be applied independently or in combination, though combined treatment approaches have been the treatment of choice in more recent years [6]. Regardless of the treatment method, high recurrence rates are still reported [1]. In clinical practice, treatment outcome analysis is considered complex due to prolonged intervention courses demanding long-term observation. In addition to objective data resulting from radiographic imaging, subjective patient satisfaction can also be taken into consideration using standardized questionnaires.

To reach our objectives, we analyzed interim and end-point results of an interdisciplinary neuroradiological and surgical treatment approach. We retrospectively extracted data of patients treated at our institution, analyzed their radiographic outcome, and conducted standardized interviews using the newly developed AQEM (Aachen Questionnaire for the Treatment of Extracranial Vascular Malformations) and the established UW-QOL (University of Washington Quality of Life Questionnaire).

Materials and methods

We reviewed University Hospital RWTH Aachen files to identify all patients with extracranial vascular malformations seen in the Department of Neuroradiology between 2012 and 2021 after obtaining approval from the Ethics Committee at the RWTH Aachen Faculty of Medicine (Statement EK 023/21). All data were collected as clinical routine and were analyzed retrospectively and anonymously. The requirement for informed consent was waived by the ethics committee. Therefore, consent of individual participants was not obtained.

In total, 51 patients with extracranial vascular malformations were seen. These consisted of 18 venous malformations (VM), 5 lymphatic malformations (LM), 8 patients with mixed venous and lymphatic malformations (VM/LM), 4 capillary malformations (CM), and 16 patients with arteriovenous malformations (AVM).

We then extracted the files of all patients diagnosed and treated with extracranial AVM of the head and neck as seen in Fig 1. Digital subtraction angiography (DSA) and magnetic resonance imaging (MRI), with demonstration of arterio-venous shunting, were used to confirm the diagnosis and collect baseline lesion volume. MRI was used for follow-up after the procedures. Additionally, two standardized questionnaires were administered to gather baseline information on symptoms, medical history, past treatment, and quality of life, as well as interim and follow-up results.

Fig 1. Flow-chart of study group selection.

Fig 1

Data collection included sex, age at which symptoms were first noticed, age of first presentation at our institution, previous treatment received, lesion location and size, symptoms, course of treatment, total fluoroscopy time, post-interventional MRI, questionnaire results, documented complications, and follow-up time.

For radiographic analysis, proof of complete obliteration (>99% devascularization) of the nidus after neuroradiological intervention and, if applicable, surgical resection was considered as cure. Any presentation of residual arteriovenous shunting was considered as incomplete treatment and implicated continuous treatment.

The standardized interviews consisted of 1) the Aachen Questionnaire for the Treatment of Extracranial Vascular Malformations (AQEM) and 2) the German translation of the University of Washington Quality of Life Questionnaire Version 4 (UW-QOL v4). Both questionnaires are provided in the supplement.

Aachen questionnaire for the treatment of extracranial vascular malformations (AQEM)

This questionnaire was developed at our institution to standardize the initial diagnostic process, address the unique needs of each patient, and document follow-up procedures in a formalized manner. It is comprised of 29 questions divided into two sections. The first section is to be completed by a clinician during the initial consultation and consists of 23 questions on symptoms relating to the differentiation between the various types of vascular malformations. Medical history and treatment goals are also noted.

The second section, with five questions, is filled out by the patient each time they present at the clinic for consultation. Patients are asked about goals achieved, their reasons for seeking further treatment, any complication that arose during treatment, and their overall satisfaction.

Washington quality of life questionnaire (UW-QOL v4)

The UW-QOL questionnaire consists of 12 single-question categories, each with three to six response options. Originally designed for patients with cancer of the head and neck, the questionnaire refers to health and physical life characteristics and to overall quality of life. Each response option is evenly scaled from 0 (worst) to 100 (best). Question categories cover pain levels, lesion appearance, patient activity and recreation, swallowing and chewing difficulty, speech, shoulder, taste, saliva, mood, and anxiety.

Results are divided into a physical subscale and a social-emotional subscale. According to the authors of the test, the mean normative reference scores are 95 ±10 for the physical subscale and 83 ±19 for the social-emotional subscale. Three global questions measure the patient’s current quality of life as compared to their status before the onset of the disease, their overall health-related quality of life and their general quality of life, all on the same 0 to 100 scale. For this study we used the German translation of the 4th version of the UW-QOL questionnaire [7].

Embolization procedure

Procedures were performed under either general anaesthesia or local anaesthesia, depending on patient condition. Access to the femoral artery was established using a 5 French or 6 French sheath. The nidus of the AVM was identified through selective angiography of the internal carotid artery (ICA) and external carotid artery (ECA). For endovascular access, a microcatheter (Rebar 18; Medtronic, Minneapolis, MN, USA) was advanced towards the nidus through the ECA. In case of vascular tortuosity, other microcatheters were used (SL10; Stryker, Kalamazoo, MI, USA or Marathon; Medtronic, Minneapolis, MN, USA) were used.

For endovascular particulate embolization, particles (Contour; Boston Scientific Corporation, Marlborough, MA, USA) were applied. For endovascular liquid embolization we used two agents (Onyx; ev3 Neurovascular, Irvine, CA, USA and Glubran 2; GEM SRL, Viareggio, Italy. For percutaneous interstitial embolization (sclerotherapy), Bleomycin mixed with contrast medium (50:50) was applied using 26–30 Gauge needles under fluoroscopic guidance.

Post-treatment, catheter angiography and MR angiography were performed to confirm successful elimination of the AVM nidus.

Surgical procedure

Surgical intervention was performed by the Department of Oral and Maxillofacial Surgery at University Hospital RWTH Aachen. For soft tissue and intramuscular AVM, excision or extirpation was performed after preoperative embolization. Legation of afferent vessels followed by excision of the AVM without visible residual masses was achieved for all patients. Particular attention was paid to preserving nerve structures. For cosmetic reconstruction, a stalked skin flap plastic or a cheek rotation skin flap was used, as needed.

For intraosseous lesions, partial resection of the involved bone or hemimandibulectomy was performed. After submarginal incision, the platysma was exposed and surged. The submandibular gland was extirpated after legation of supplying vessels. Exposure of the carotid sheath improved line of sight to vascular structures for subsequent anastomosis. After temporarily tying off the lingual artery, the affected area of the mandible was detached and sent to the Institute of Pathology for examination. Replacement was provided with an osteocutaneous or musculocutaneous transplantation of iliac crest or fibula. To provide accurately fitted transplants, digital construction of templates with the help of computer software (ProPlan CMF; DePuy Synthes, West Chester, PA, USA) was used. The templates were intraoperatively fitted to the harvest bone site by screws, providing the exact dimension of the needed transplant. Making use of the previously exposed vascular structures, the transplants were attached with osteosynthesis sheets and bloodflow was restored. Significant effort was made to minimize ischemic time and ensure adequate perfusion of the transplant bone marrow post-implementation.

Patients with hemimendibulectomy or bone resection had their airways secured with temporary tracheotomy; in all other cases, endotracheal intubation was performed. Post-surgical patients were placed in an intensive or intermediate care unit and monitored for immediate surgical complications or haemorrhage. Patient condition and vital signs were monitored for a minimum of 24 hours. Clinical follow-up consultations were established in intervals of three to six weeks after discharge from our hospital.

Statistical analysis

For statistical analysis we used cross-table, Pearson and Spearman calculations. All statistical analyses were performed with a software platform (SPSS Version 27.0; IBM, Armonk, NY, USA).

Results

Of the 51 patients with vascular malformations (AVM, VM, LM, Capillary Malformation) who were seen by our Neuroradiology Department between 2012 and 2021, 16 were diagnosed with an extracranial AVM of the head and neck region. Ten of those patients were scheduled for interdisciplinary treatment which was introduced in 2012 in collaboration with the Department of Oral and Maxillofacial Surgery, and thus comprised our study group.

There were 8 females and 2 males, with a mean age of 33.5 ±16.8 years (range 11–61 years) at first presentation. Four patients had not undergone any treatment while the other six patients had previously received treatment, including surgical interventions, embolization procedures and laser or cryotherapy. A comprehensive overview of the study group’s demography is provided in Table 1.

Table 1. Demographic characteristics of study group.

Patients in study group 10
Male / Female 2 / 8
Mean age (Range) in years 33.5 (11–61)
Previously treated patients 6
Previous treatment *
 Surgery
 Embolization
 Laser
 Cryotherapy

3
4
1
1
AVM intramuscular / intraosseous 7 / 3

* Multiple treatment may apply.

In 6 patients (60%), the AVM lesion was located in soft tissue only. In one patient (10%), the lesion was located in bone tissue only. The remaining 3 patients (30%) had a combined intraosseous and soft tissue lesion.

In 3 of the 10 patients (30%), the AVM was located on the nose, in 2 (20%) the lesion was in the cheek and lip, and 5 patients (50%) had intraoral involvement. All combined intraosseous and soft tissue AVM were located intraorally. The mean volume of the lesions before treatment was 70.8 ±63.1 ml (10.1–167.4 ml).

The mean age, at which symptoms were first noticed was 19.9 ±18.7 years (1–57 years). All 10 patients (100%) experienced swelling. Discoloration of the skin occurred in 50% (5/10) of cases, bleeding in 30% (3/10), and a pulsating sensation in 20% (2/10). The lesion volume had progressed over time in all patients (10/10). Nine out of ten patients responded to the question about the reasons they sought treatment as follows: Appearance in 66.7% (6/9); difficulty in chewing in 44.4% (4/9); paresthesia in 44.4% (4/9); pain in 33.3% (3/9); reduced mental well-being in 22.2% (2/9); bleeding in 22.2% (2/9); difficulties in swallowing in 11.1% (1/9); and difficulties with speech in 11.1% (1/9).

All ten patients underwent endovascular embolization. In 6 patients, endovascular treatment was comprised solely of particle embolization. One patient was treated with a combination of particle and coil embolization, and a second patient received a combination of particle embolization and sclerotherapy using Bleomycin. A third patient received liquid embolization only using both Onyx and Glubran, while one other patient received combined particle, Bleomycin, Aethoxysklerol and Glubran embolization. Mean accumulated fluoroscopy time during the embolization procedures was 101.7 ±43.5 minutes (29.9–192.7 minutes).

Nine patients underwent surgery after the endovascular treatment; one of the ten patients refused surgical resection. The mean time between embolization procedure and surgical intervention was 3.3 ±4.1days (1–14 days).

After treatment, eight of the ten patients underwent follow-up imaging and radiographic evaluation; one patient had permanent residency out of country, and one patient refused. Re-evaluation of the lesions via MRI or angiography showed complete obliteration of the nidus, considered as cure in five of the eight patients (62.5%). A mean time of 1066 ±693.8 days (376–2004 days) had passed since treatment. The three remaining patients presented with residual niduses and were under continuous treatment at the time of analysis.

Patients who had finished treatment were hospitalized for a median of 12 (Interquartile range 7–47) days. All but two patients experienced minor adverse effects, limited to the region of former lesion. Minor side effects included paresthesia, swelling and pain. In all cases, side effects were managed conservatively. None of the patients experienced major complications, in accordance with the Society of Interventional Radiology (SIR) classification [8].

In the AQEM questionnaire, 77.7% (7/9) of patients were very satisfied or mostly satisfied with the course of treatment. Two patients were undecided about their satisfaction with treatment. None of the patients showed dissatisfaction. When looking at the subgroups, 80% (4/5) of radiographically cured patients, and 66.7% (2/3) of radiographically incomplete treated patients reported to be very satisfied or mostly satisfied.

In the UW-QOL v4 questionnaire, patients showed a mean score of 89.3 ±11.8 (61.7–100) in the physical subscale (the mean normative reference score is 95 ±10). The mean score in the social-emotional subscale for our patient collective was 82.5 ±17.4 (50–100) (the mean normative reference score for this subscale is 83 ±19). Two patients did not participate in the interview.

When asked about their treatment goals, patients reported a mean of 2.7 ±1.8 (1–6) symptoms they desired to improve before the initial treatment at our institution. After initiation of the treatment, patients reported a mean of 1.1 ±1.1 (0–3) symptoms, showing a significant decrease in symptoms over the treatment period (p = 0.002).

Complete follow-up data sets (neuroradiological imaging and interviews) were collected from 7 of the 10 patients; one patient had permanent residency abroad and did not participate in follow-up imaging or interviews. Two patients participated in the interview only and did not undergo follow-up imaging. A comprehensive overview of the treatment and outcome in the study group is provided in Table 2.

Table 2. Comprehensive overview of results in the study group.

Case Sex Age Previous treatment Location Initial Size [mm] Treatment Flouroscopy time [min] Outcome Adverse effects Radiographic Follow-Up [days]
Neuroradiology Surgery
1 m 47 None Nose Soft tissue 35x20x15 Particles/ Bleomycin Excision 125.7 Cure Paraesthesia 2004
2 f 11 Embolization Floor of mouth Soft tissue / Intraosseous 79x36x51 Particles Hemimandibulectomy / Osteocutaneous fibula transplant 114.5 Failed to contact
3 f 12 None Mandible, Floor of mouth Soft tissue/ Intraosseous 71x21x40 Particles Excision 62.5 Cure Paraesthesia 1456
4 f 31 Excision Cheek, Lip Soft tissue 32x15x21 Particles Excision 29.9 No relaps in questionnaire None None
5 f 30 Embolization/Excision Mandible, Floor of mouth Soft tissue/ 42x73x53 Particles Excision / ALT-Transplant 90.9 Cure Praesthesia, Bleeding 1075
Intraosseous
6 f 42 Laser/Excision Cheeck, Lip, Intraoral Soft tissue lower lip:18x11x27 upper lip:15x7x12 tongue: 15x50x22 Particles/ Bleomycin/ Refused 88.6 Ongoing treatment Pain, Discoloration Current treatment
Aethoxysklerol/
Glubran
7 f 61 Biopsy Nose Soft tissue 44x63x14 Particles Excision / Stalked skin flap 192.7 Ongoing treatment Aesthetic Current treatment
8 m 51 Laser/ Cryotherapy Nose Soft tissue 41x28x25 Particles/Coils Excision / Stalked skin flap / Cheek rotation skin flap 80.9 Ongoing treatment None Current treatment
9 f 18 Embolization Mandible, Floor of mouth Intraosseous 62x50x54 Particles Hemimandibulectomy / Osteocutaneous fibula transplant 106.0 Cure Abscess 420
10 f 32 None Mandible, Floor of mouth Soft tissue 48x36x36 Onyx/Glubran Extirpation 125.2 Cure Paraesthesia, Pain, Swelling 376

f = female, m = male, ALT-Transplant = anterolateral thigh transplant.

Discussion

Interventional embolization and surgical resection are both established approaches for definite treatment of extracranial AVM of the head and neck. However, a recent meta-analysis of published studies involving interventional treatment of this condition showed that there is currently no treatment or reporting standard for extracranial AVM of the head and neck, and that the methodological quality of available publications is too heterogeneous to draw conclusions on optimal treatment strategies [9]. To cite just one example, some authors have termed devascularization rates of 90% as "cure", while others have presented treatment results without any radiographic modality for follow-up [1012].

To the best of our knowledge, no prospective clinical study has been published on this disease. Minimum requirements and standards were recommended for all clinical studies on the treatment of extracranial AVM of the head and neck to ensure sufficient data for the development of an evidence-based treatment strategy. These include: 1) a dynamic and/or angiographic imaging modality confirming the AVM and distinguishing it from other vascular entities; 2) a detailed description of the therapeutic management; 3) the definition of a devascularization of greater than 99% for complete resolution; 4) a follow-up time of at least one year with post-treatment radiographic imaging. Additionally, we hypothesize that questionnaires may also be a helpful tool to evaluate treatment strategies and measure patient satisfaction.

In line with recent recommendations, treatment protocol for extracranial AVM at our institution consists of a combination of endovascular embolization followed by surgical resection [6]. In this study we retrospectively analyzed our results using the above-mentioned reporting standards. Radiographic resolution (cure) was achieved in 62.5% of patients with a mean follow-up period of 1066 days. In the questionnaires we used, 80% of cured patients were satisfied with treatment. Significantly fewer symptoms were reported after treatment. No major complications occurred in our study group. Minor sensory deficits and aesthetic affectation were reported by the patients during follow-up consultation and need to be further addressed for complete patient satisfaction. Overall, the rate and extent of complications has been shown to be acceptable to both patients and treating physicians.

Our results appear compatible with other publications. In studies where endovascular therapy was the sole treatment modality, or where endovascular therapy was combined with surgery, rates for “success” or “improved condition” ranged between 44% and 100% [10,11,1331]. We believe that the heterogeneity of reporting standards used by the studies outlined in other publications is too large to allow definitive conclusions on therapeutic efficacy. Objective definitions or reproducible proxies for successful treatment are often missing and follow-up procedures are inconsistent. Moreover, useful outcome measurement tools for extracranial AVM that reflect all aspects have yet to be developed [32].

In coronary interventions, prolonged fluoroscopy has been shown to indicate higher procedure complexity [33]. Voluminous intracranial AVM, too, could assumptively have a higher risk for morbidity and mortality [34]. However for extracranial AVM of the head and neck, we did not identify a significant correlation between total fluoroscopy time and initial volume of the lesion (p = 0.814). Fluoroscopy time and radiographic result did not have a significant correlation either (p = 0.895). To illustrate this, in case #1, where the lesion volume was 10.5 ml and fluoroscopy time during intervention 125.7 minutes, the lesion was completely resolved on MRI after one year follow-up. In case #5, with an initial lesion volume of 162.5 ml and a fluoroscopy time of 90.9 minutes, the lesion was also completely resolved. Therefore, fluoroscopy time can neither be used as a surrogate marker for lesion volume or complexity, nor as a predictor for the result. Scatter diagrams for both correlations are provided in the supplement.

Subjective patient satisfaction surveys have been used to measure outcome alongside other quality of treatment indicators [35]. However, their validity has been controversially discussed [36]. In our interviews, 80% of cured patients (>99% devascularization in radiographic imaging) reported to be very satisfied or mostly satisfied with the treatment at our institution. This is supported by the social emotional subscale score in the UW-QOL with a mean patient score of 82.5 points, which is within the range of the healthy population. With regard to this, patients experience less of a deficit than radiographic outcomes suggest. The UW-QOL may not be ideal for our study group, however, since it was originally designed for patients with cancer of the head and neck [37]. Subjective patient satisfaction may be one indicator for treatment that needs more attention for outcome analysis in addition to radiographic studies.

With the development of the AQEM questionnaire as patient reported outcome measure, we have established a tool to closely monitor and adjust treatment strategies as required. Future prospective trials and long-term observation studies ought to be conducted to verify this hypothesis.

Conclusion

Our results indicate that our protocol to treat extracranial AVM of the head and neck using preoperative embolization and consecutive surgical resection is both effective and feasible and lead to high patient satisfaction. However, more published articles using appropriate reporting standards and prospective clinical studies are needed to identify comprehensive outcome proxies and develop optimal treatment protocols for these lesions, which are challenging to treat and considerably undermine patients’ quality of life.

Supporting information

S1 Supplement. AQEM questionnaire.

(PDF)

S2 Supplement. UW-QOL v4 questionnaire.

(PDF)

S3 Supplement. Scatter diagram for correlation between fluoroscopy time and initial lesion size.

(DOCX)

S4 Supplement. Scatter diagram for correlation between fluoroscopy time and radiographic outcome.

(DOCX)

S5 Supplement. Full data set.

(XLSX)

Acknowledgments

We would like to express our special thanks of gratitude to our friend, Sara Fraser, who has supported our work with her language skills and proofread the manuscript.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Kohout MP, Hansen M, Pribaz JJ, Mulliken JB. Arteriovenous malformations of the head and neck: natural history and management. Plast Reconstr Surg. 1998;102(3):643–54. doi: 10.1097/00006534-199809030-00006 [DOI] [PubMed] [Google Scholar]
  • 2.Liu AS, Mulliken JB, Zurakowski D, Fishman SJ, Greene AK. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast Reconstr Surg. 2010;125(4):1185–94. doi: 10.1097/PRS.0b013e3181d18070 [DOI] [PubMed] [Google Scholar]
  • 3.Dasgupta R, Fishman SJ. ISSVA classification. Semin Pediatr Surg. 2014;23(4):158–61. doi: 10.1053/j.sempedsurg.2014.06.016 [DOI] [PubMed] [Google Scholar]
  • 4.Yih WY, Ma GS, Merrill RG, Sperry DW. Central hemangioma of the jaws. J Oral Maxillofac Surg. 1989;47(11):1154–60. doi: 10.1016/0278-2391(89)90005-0 [DOI] [PubMed] [Google Scholar]
  • 5.Hsu YC, Huang SY, Chou CM. Giant congenital arteriovenous malformation over right upper limb causing heart failure. Asian J Surg. 2020. doi: 10.1016/j.asjsur.2020.05.035 [DOI] [PubMed] [Google Scholar]
  • 6.Fernandez-Alvarez V, Suarez C, de Bree R, Nixon IJ, Makitie AA, Rinaldo A, et al. Management of extracranial arteriovenous malformations of the head and neck. Auris Nasus Larynx. 2020;47(2):181–90. doi: 10.1016/j.anl.2019.11.008 [DOI] [PubMed] [Google Scholar]
  • 7.Rogers SN. University of Washington Quality of Life Questionnaire (UW-QOL v4 and v4.1) 2020 [Available from: http://www.hancsupport.com/professionals/quality-life/qol-questionnaires/uw-qol/uw-qol-v4-translations.
  • 8.Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199–202. doi: 10.1097/01.rvi.0000094584.83406.3e [DOI] [PubMed] [Google Scholar]
  • 9.Lilje D, Wiesmann M, Hasan D, Riabikin A, Ridwan H, Hölzle F, et al. Interventional therapy of extracranial arteriovenous malformations of the head and neck–A systematic review. PLOS ONE. 2022; 17(7): e0268809. doi: 10.1371/journal.pone.0268809 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Meila D, Grieb D, Greling B, Melber K, Jacobs C, Hechtner M, et al. Endovascular treatment of head and neck arteriovenous malformations: long-term angiographic and quality of life results. J Neurointerv Surg. 2017;9(9):860–6. doi: 10.1136/neurintsurg-2016-012570 [DOI] [PubMed] [Google Scholar]
  • 11.Gupta AK, Purkayastha S, Bodhey NK, Kapilamoorthy TR, Krishnamoorthy T, Kesavadas C, et al. Endovascular treatment of scalp cirsoid aneurysms. Neurol India. 2008;56(2):167–72. doi: 10.4103/0028-3886.41995 [DOI] [PubMed] [Google Scholar]
  • 12.Zhao XP, Huang ZQ, Chen WL, Wang YY, Lin ZY. Percutaneous sclerotherapy of arteriovenous malformations of the face using fibrin glue combined with OK-432 and bleomycin after embolisation. Br J Oral Maxillofac Surg. 2016;54(2):187–91. doi: 10.1016/j.bjoms.2015.11.020 [DOI] [PubMed] [Google Scholar]
  • 13.Han Y, Fan X, Su L, Wang Z. Absolute Ethanol Embolization Combined with Surgical Resection of Scalp Arteriovenous Malformations: Interim Results. J Vasc Interv Radiol. 2018;29(3):312–9. doi: 10.1016/j.jvir.2017.10.005 [DOI] [PubMed] [Google Scholar]
  • 14.Wang D, Su L, Han Y, Wang Z, Zheng L, Fan X. Absolute Ethanol Embolisation of Mandibular Arteriovenous Malformations Following Direct Percutaneous Puncture and Release of Coils via a Microcatheter. Eur J Vasc Endovasc Surg. 2017;53(6):862–9. doi: 10.1016/j.ejvs.2017.01.022 [DOI] [PubMed] [Google Scholar]
  • 15.Su L, Wang D, Han Y, Wang Z, Fan X. Salvage treatment of hemorrhagic arteriovenous malformations in jaws. J Craniomaxillofac Surg. 2015;43(7):1082–7. doi: 10.1016/j.jcms.2015.06.007 [DOI] [PubMed] [Google Scholar]
  • 16.Kim B, Kim K, Jeon P, Kim S, Kim H, Byun H, et al. Long-term results of ethanol sclerotherapy with or without adjunctive surgery for head and neck arteriovenous malformations. Neuroradiology. 2015;57(4):377–86. doi: 10.1007/s00234-014-1483-3 [DOI] [PubMed] [Google Scholar]
  • 17.Pekkola J, Lappalainen K, Vuola P, Klockars T, Salminen P, Pitkaranta A. Head and neck arteriovenous malformations: results of ethanol sclerotherapy. AJNR Am J Neuroradiol. 2013;34(1):198–204. doi: 10.3174/ajnr.A3180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pompa V, Brauner E, Bresadola L, Di Carlo S, Valentini V, Pompa G. Treatment of facial vascular malformations with embolisation and surgical resection. Eur Rev Med Pharmacol Sci. 2012;16(3):407–13. [PubMed] [Google Scholar]
  • 19.Kang GC, Song C. Forty-one cervicofacial vascular anomalies and their surgical treatment—retrospection and review. Ann Acad Med Singapore. 2008;37(3):165–79. [PubMed] [Google Scholar]
  • 20.Pompa V, Valentini V, Pompa G, Di Carlo S, Bresadola L. Treatment of high-flow arteriovenous malformations (AVMs) of the head and neck with embolization and surgical resection. Ann Ital Chir. 2011;82(4):253–9. [PubMed] [Google Scholar]
  • 21.Richter GT, Suen JY. Clinical course of arteriovenous malformations of the head and neck: a case series. Otolaryngol Head Neck Surg. 2010;142(2):184–90. doi: 10.1016/j.otohns.2009.10.023 [DOI] [PubMed] [Google Scholar]
  • 22.Fan XD, Su LX, Zheng JW, Zheng LZ, Zhang ZY. Ethanol embolization of arteriovenous malformations of the mandible. AJNR Am J Neuroradiol. 2009;30(6):1178–83. doi: 10.3174/ajnr.A1539 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Chen WL, Ye JT, Xu LF, Huang ZQ, Zhang DM. A multidisciplinary approach to treating maxillofacial arteriovenous malformations in children. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(1):41–7. doi: 10.1016/j.tripleo.2009.03.006 [DOI] [PubMed] [Google Scholar]
  • 24.Ishimaru H, Yoshimi S, Akita S. Treatment of Periorbital and Palpebral Arteriovenous Malformations. Adv Wound Care (New Rochelle). 2019;8(6):256–62. doi: 10.1089/wound.2018.0846 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kitagawa A, Izumi Y, Hagihara M, Kamei S, Ikeda S, Katsuda E, et al. Ethanolamine oleate sclerotherapy combined with transarterial embolization using n-butyl cyanoacrylate for extracranial arteriovenous malformations. Cardiovasc Intervent Radiol. 2014;37(2):371–80. doi: 10.1007/s00270-013-0653-8 [DOI] [PubMed] [Google Scholar]
  • 26.Dabus G, Linfante I, Benenati J, Perlyn CA, Martinez-Galdamez M. Interventional management of high-flow craniofacial vascular malformations: a database analysis and review of the literature. J Neurointerv Surg. 2017;9(1):92–6. doi: 10.1136/neurintsurg-2016-012315 [DOI] [PubMed] [Google Scholar]
  • 27.Deng W, Huang D, Chen S, Zhang X, Li X, Li J, et al. Management of high-flow arteriovenous malformation in the maxillofacial region. J Craniofac Surg. 2010;21(3):916–9. doi: 10.1097/SCS.0b013e3181d880fd [DOI] [PubMed] [Google Scholar]
  • 28.Bhandari PS, Sadhotra LP, Bhargava P, Bath AS, Mukherjee MK, Maurya S. Management strategy for facial arteriovenous malformations. Indian J Plast Surg. 2008;41(2):183–9. doi: 10.4103/0970-0358.44943 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Phillips J, Tang C, Armstrong D, De Chalain T, Zuker R. Congenital arteriovenous malformations: A follow-up of treatment. Can J Plast Surg. 2005;13(1):23–6. doi: 10.1177/229255030501300108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Churojana A, Chiewwit P, Chuangsuwanich A, Aojanepong C, Chawalaparit O, Suthipongchai S. Embolization of vascular malformations in head and neck regions. A single center experience. Interv Neuroradiol. 2004;10(1):37–46. doi: 10.1177/159101990401000103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Thiex R, Wu I, Mulliken JB, Greene AK, Rahbar R, Orbach DB. Safety and clinical efficacy of Onyx for embolization of extracranial head and neck vascular anomalies. AJNR Am J Neuroradiol. 2011;32(6):1082–6. doi: 10.3174/ajnr.A2439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Horbach SER, Rongen APM, Elbers RG, van der Horst C, Prinsen CAC, Spuls PI, et al. Outcome measurement instruments for peripheral vascular malformations and an assessment of the measurement properties: a systematic review. Qual Life Res. 2020;29(1):1–17. doi: 10.1007/s11136-019-02301-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Nikolsky E, Pucelikova T, Mehran R, Balter S, Kaufman L, Fahy M, et al. An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention. J Invasive Cardiol. 2007;19(5):208–13. [PubMed] [Google Scholar]
  • 34.Hamilton MG, Spetzler RF. The prospective application of a grading system for arteriovenous malformations. Neurosurgery. 1994;34(1):2–6; discussion -7. [PubMed] [Google Scholar]
  • 35.Jackson JL, Kroenke K. Patient satisfaction and quality of care. Mil Med. 1997;162(4):273–7. [PubMed] [Google Scholar]
  • 36.Vuori H. Patient satisfaction—does it matter? Qual Assur Health Care. 1991;3(3):183–9. doi: 10.1093/intqhc/3.3.183 [DOI] [PubMed] [Google Scholar]
  • 37.Rogers SN, Lowe D. Screening for dysfunction to promote multidisciplinary intervention by using the University of Washington Quality of Life Questionnaire. Arch Otolaryngol Head Neck Surg. 2009;135(4):369–75. doi: 10.1001/archoto.2009.7 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Andrej M Kielbassa

28 Jun 2022

PONE-D-22-08407Interventional embolization combined with surgical resection for treatment of extracranial AVM of the head and neck: A monocenter intention-to-treat analysisPLOS ONE

Dear Dr. Nikoubashman, please note that the previously assigned Editor has cancelled his cooperation with Plos One recently. I have stepped in here yesterday, so please accept our apologies for any delay with this review process.

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Having intensively reviewed your revised draft, our external reviewers differed to some extent with their final recommendations. Additionally, I have double checked your submitted version, to come to a more balanced decision (see R #3). All in all, I am convinced that your re-revised paper will be worth following, even if your current version still would benefit from thorough re-edits and some language polishing. Thus, I would like to encourage you to provide a thorough (in terms of language, reviewers' constructive criticism, content, generalizable outcome, and/or Authors' Guidelines) revision in order to avoid an iterative and lengthy review process and facilitate a smooth publication process.

Please submit your revised manuscript by Aug 12 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Andrej M Kielbassa, Prof. Dr. med. dent. Dr. h. c.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors should be complimented for their manuscript. It gives important insights into the treatment of a very rare disease and the patient number is for such a disease reasonable with 10 patients. Their conclusion is warranted by their experience.

However, there are a few minor points to address:

Title:

As this is a retrospective analysis, how can it be an intention to treat analysis? In my opinion this is only possible in prospective studies.

Abstract:

“Patients treated according to our protocol show a high satisfaction rate, regardless of the radiographic outcome.” Please use past tense (showed)

Advances in knowledge:

In my opinion the statement is too strong, please consider changing it to “..might be an effective..”

General comment:

Sometimes the mean is used and sometimes the median. It should be checked if in cases of mean normality is given.

The results are presented in a transparent way and the conclusions are warranted by the results. The discussion is well written and all relevant literature was cited.

Reviewer #2: The paper by Lije et al. analyzed the efficacy and feasibility of combined (interventional embolization plus surgery) for the treatment of extracranial AVMs by analyzing objective parameters (i.e., radiographic proof of obliteration, adverse effects) as well as subjective parameters (AQUEM questionnaire, UW-QOL v4 questionnaire). Therefore, of all patients with vascular malformations seen by the Institution's Department of Neuroradiology between 2012 and 2021, those with an extracranial AVM scheduled for interdisciplinary treatment were retrospectively analyzed.

The article shows all essential data regarding patient, intervention, and outcome. It is well structured in its methodology and thereby provides comprehensible results. The results are well defined, and the findings are well embedded and addressed in the discussion. Although the analyzed cases are relatively low, the general message that combined treatment is practical and feasible in selected patients is well supported.

Two statements seem unclear and could be enhanced with minor revisions:

- In line 169, you state that surgery was performed within seven days of the embolization procedure; however, in line 238, the range for the time between procedure and surgery is 1-14d.

- in your results (line 242), you state that five of eight patients were considered cured, but in supplement four, there seem to be four in the whole group and four in the incomplete group (Misplacement of Case 9?); Does that influence the statistical calculations as well?

I am happy to look at the revised version and congratulate you on the excellent work.

Reviewer #3: This paper has been well elaborated, no doubt. Notwithstanding, the Authors have missed to strictly follow the Journal style, see Guidelines, and consult some recently published Plos One papers.

- With your Abstract section, please please provide as much information as possible within the allowed 300-word limit. Add p values with your most prominent results. Style must be "(p < 0.001)", or "(p = 0.012)".

- Reference style has to be adapted to the Journal guidelines. "(...) and can be evident at birth.(1)" must read "(...) and can be evident at birth¹."

- With ALL materials (including chemicals) and methodologies (including statistical software), please use general names with your text, followed by (brand name; manufacturer, city, St[ate, abbreviated, if US], country) in parentheses. Stick to semicolon. Revise thoroughly.

- With your Conclusions, please stick exclusively to your revised aims. Do not simply repeat your results here. Do not speculate on future studies. Instead, provide a reasonable and generalizable extension of your outcome.

- Please revise your reference list for uniform formatting. Style would be "Kasraei S, Sami L, Hendi S, Alikhani MY, Rezaei-Soufi L, Khamverdi Z. Antibacterial properties of composite resins incorporating silver and zinc oxide nanoparticles on Streptococcus mutans and Lactobacillus. Restor Dent Endod. 2014; 39(2): 109–114. https://doi.org/10.5395/rde.2014.39.2.109 PMID: 24790923" Provide doi and PMID numbers.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Sep 1;17(9):e0273018. doi: 10.1371/journal.pone.0273018.r002

Author response to Decision Letter 0


12 Jul 2022

Dear Editors,

Dear reviewers,

We would like to thank you for the thoughtful and favorable reviews and the opportunity to revise our manuscript. We believe that our manuscript has benefitted considerably from the remarks, and we hope that we addressed the mentioned issues to your satisfaction.

Below you can find our responses to the reviewer’s comments in red. Please also find attached our revised manuscript in two versions: with and without tracked changes.

Additionally, we have added the full data set of our study as supplement S5 file.

We are happy to hear from you if you have any other question.

With our highest regards,

The authors

Reviewer #1: […]

Title: As this is a retrospective analysis, how can it be an intention to treat analysis? In my opinion this is only possible in prospective studies.

We would like to thank the reviewers as he/she accurately points out that an intention-to-treat analysis is defined as a prospective study design. We have made according changes in the title:

Interventional embolization combined with surgical resection for treatment of extracranial AVM of the head and neck: A monocentric retrospective analysis

Abstract:

“Patients treated according to our protocol show a high satisfaction rate, regardless of the radiographic outcome.” Please use past tense (showed)

We would like to give thanks to the reviewer for the correction of this mistake. We changed the sentence into past tense.

Patients treated according to our protocol showed a high satisfaction rate, regardless of the radiographic outcome.

(Clean copy lines 52-53)

Advances in knowledge:

In my opinion the statement is too strong, please consider changing it to “..might be an effective..”

In consideration of the small sample size and the rarity of the condition, the reviewer is correct that a less strong wording might be helpful to stimulate a discussion.

The results of this study indicate that embolization followed by surgical resection might be an effective treatment for extracranial AVM of the head and neck and is accompanied by high patient satisfaction.

(Clean copy lines 57-59)

[…]

Sometimes the mean is used and sometimes the median. It should be checked if in cases of mean normality is given.

We would like to thank the reviewer for the helpful remark to check the usage of the mean and median. We used the mean for statistical analysis wherever the distribution of data was expected to be symmetrical (e.g. patients’ age, lesion volume, accumulated fluoroscopy time), or if reference scores where provided as such (e.g. in the UW-QOL v4 questionnaire). The median was used only in reference to the hospitalization time, where outliers could be identified as shown in the comprehensive overview of the study group (Table 2). In careful attention of these statistical aspects, we deem the utilization to be appropriate.

Reviewer #2: […]

Two statements seem unclear and could be enhanced with minor revisions:

- In line 169, you state that surgery was performed within seven days of the embolization procedure; however, in line 238, the range for the time between procedure and surgery is 1-14d.

The reviewer is correct to point out the mismatching specification of time between embolization procedure and surgery. The passage on the surgical procedure merely tries to give an overview on the course of action of the procedure. The timeframe of seven days was communicated between the neuroradiological and surgical department to facilitate smooth workflow. To prevent the number in this section to be confused as part of the results, we erased the section.

Surgical intervention was performed by the Department of Oral and Maxillofacial Surgery at University Hospital RWTH Aachen.

(Clean copy lines 165-166)

- in your results (line 242), you state that five of eight patients were considered cured, but in supplement four, there seem to be four in the whole group and four in the incomplete group (Misplacement of Case 9?); Does that influence the statistical calculations as well?

We would like to thank the reviewer for this very important note. There was indeed a mistake in the scatter diagram and case #9 was wrongfully placed in the “incomplete” group. This has no effect on the calculations as they were performed independently. The revised copy of the scatter diagrams can be found in file S3 Supplement 3 and file S4 Supplement 4.

Supplement 3. Scatter diagram for correlation between fluoroscopy time and initial lesion size (p=0.814).

Supplement 4. Scatter diagram for correlation between fluoroscopy time and radiographic outcome (p=0.895).

Reviewer #3:

- With your Abstract section, please please provide as much information as possible within the allowed 300-word limit. Add p values with your most prominent results. Style must be "(p < 0.001)", or "(p = 0.012)".

We are happy for the reviewer to bring this aspect to our attention. As most of the findings are of descriptive nature and significance of comparison had lower priority in the analysis, the highlights of the results are listed in the abstract. We have added the significant decrease of symptoms (p=0.002) as another prominent finding.

Radiographic resolution was achieved in 62.5% of cases and a significant decrease of symptoms was identified (p=0.002). None of the patients reported dissatisfaction and no major complications occurred.

(Clean copy lines 45-47)

- Reference style has to be adapted to the Journal guidelines. "(...) and can be evident at birth.(1)" must read "(...) and can be evident at birth¹."

We would like to thank the reviewer for this remark. All citations have been adapted accordingly.

- With ALL materials (including chemicals) and methodologies (including statistical software), please use general names with your text, followed by (brand name; manufacturer, city, St[ate, abbreviated, if US], country) in parentheses. Stick to semicolon. Revise thoroughly.

The reviewer brings up a very good point that interrupted the flow of reading significantly. We have corrected the sections according to the recommendations.

- With your Conclusions, please stick exclusively to your revised aims. Do not simply repeat your results here. Do not speculate on future studies. Instead, provide a reasonable and generalizable extension of your outcome.

This remark by the reviewer was very helpful for the authors to reconsider the key findings of the article and sparked a fruitful discussion. With the presented treatment protocol and its results, we are certain to only show one possible way of managing this rare condition. In view of existing literature, the conclusion of the article may best be as cautious as outlined in the current manuscript to give room and motivation for further studies. However, if changes in the regard to this aspect are needed, we are happy to adapt the manuscript.

- Please revise your reference list for uniform formatting. Style would be "Kasraei S, Sami L, Hendi S, Alikhani MY, Rezaei-Soufi L, Khamverdi Z. Antibacterial properties of composite resins incorporating silver and zinc oxide nanoparticles on Streptococcus mutans and Lactobacillus. Restor Dent Endod. 2014; 39(2): 109–114. https://doi.org/10.5395/rde.2014.39.2.109 PMID: 24790923" Provide doi and PMID numbers.

The reviewer is correct to bring this point to our attention. We have made changes in the bibliography according to the recommendations in the PLOS submission guidelines. We provided the PMID if DOI could not be obtained.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Andrej M Kielbassa

1 Aug 2022

Interventional embolization combined with surgical resection for treatment of extracranial AVM of the head and neck: A monocentric retrospective analysis

PONE-D-22-08407R1

Dear Dr. Nikoubashman,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Congratulations, and stay healthy!

Kind regards,

Andrej M Kielbassa, Prof. Dr. med. dent. Dr. h. c.

________________________________________

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Andrej M Kielbassa

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All comments wäre adressed.

Reviewer #2: In the revised version of this manuscript, the reviewer's comments have been integrated in a valuable way, and the manuscript has profited substantially.

It is still a tiny series but a thorough workup and evaluation of the cases, providing an excellent base for further studies and fruitful discussion on that topic.

I congratulate the authors for their work.

Reviewer #3: This revised and re-submitted draft has been considerably improved, and all comments have been adequately addressed. This manuscript is considered ready to proceed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

Acceptance letter

Andrej M Kielbassa

22 Aug 2022

PONE-D-22-08407R1

Interventional embolization combined with surgical resection for treatment of extracranial AVM of the head and neck: A monocentric retrospective analysis

Dear Dr. Nikoubashman:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Dr. med. dent. Dr. h. c. Andrej M Kielbassa

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Supplement. AQEM questionnaire.

    (PDF)

    S2 Supplement. UW-QOL v4 questionnaire.

    (PDF)

    S3 Supplement. Scatter diagram for correlation between fluoroscopy time and initial lesion size.

    (DOCX)

    S4 Supplement. Scatter diagram for correlation between fluoroscopy time and radiographic outcome.

    (DOCX)

    S5 Supplement. Full data set.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES